[Menthol in the adjuvant treatment of gallbladder stones fragmented by ESWL as an option for reducing doses of urso- and chenodeoxycholic acid]. / Mentholsubstitution als Option zur Dosisreduktion von Urso- und Chenodeoxycholsäure in der adjuvanten Therapie nach ESWL von Gallenblasensteinen.

BACKGROUND: Assessments of the litholytic activity of terpenes in the conservative treatment of gallstone disease vary. Achievement of a stone-free state through dissolution of residual fragments after extracorporeal shock wave lithotripsy (ESWL) is a suitable model for investigating the litholytic activity of menthol. PATIENTS AND METHODS: After ESWL in patients with symptomatic gallbladder stones, the litholytic efficacy of the standard therapy of 125 mg urso-/chenodeoxycholic acid (UDC/CDC) per 25 kg body weight (UDC + CDC) was compared with that of 62.5 mg UDC/CDC plus 125 mg menthol (M) per 25 kg body weight (M + UDC + CDC). 70 patients were treated with M + UDC + CDC (n = 36) or UDC + CDC (n = 34) in a double-blind design. RESULTS: 19 of 34 patients (55.9%) in the UDC + CDC group became stonefree in an average period of 5.9 months, compared with 17 out of 36 patients (47.2%) in the M + UDC + CDC group in 8.8 months. Although the patients on UDC + CDC became stone-free significantly more quickly (p = max [p1,p2] = 0.4717), there was no relevant statistical difference in the total number of stone-free patients between the two treatment groups. After subtraction of the patients who terminated the study prematurely, significantly larger numbers of stone-free patients under the standard therapy were found at 9 and 12 months (16 : 9 and 19 : 12, respectively), while at the other time points no significant difference was found. Before ESWL, seven of 25 patients in the menthol group had two or more stones, while in the group treated with the standard therapy this was only the case in two patients. Five patients had mild calcification on admission to the study, four of whom received M + UDC + CDC. CONCLUSION: Overall, patients become stone-free more quickly on the standard UDC + CDC therapy. However, after subtraction of the patients who discontinued the study prematurely it can be seen that this results from significantly higher numbers of stone-free patients at 9 and 12 months, so that over the entire observation period-and in consideration of the less favorable stone parameters in the menthol group-there is no substantial statistically relevant difference in the efficacy of the two treatments.

Frequency of bacteremia after linear EUS of the upper GI tract with and without FNA.

BACKGROUND: Few data are available concerning the frequency of bacteremia after diagnostic EUS or EUS-guided FNA. This study was undertaken to provide these data and to determine whether present guidelines for prophylactic administration of antibiotics to prevent endocarditis during upper endoscopy are applicable to EUS and EUS-guided FNA. METHODS: A total of 100 patients who were to undergo diagnostic EUS of the upper-GI tract and 50 who were to have upper-GI EUS-guided FNA were enrolled in this prospective study. Blood cultures were obtained before and within 5 minutes after the conclusion of the procedure. In case of bacterial growth, patients were observed for at least 3 days for signs of infection. RESULTS: After diagnostic EUS, significant bacteremia was found in two patients with esophageal carcinoma (2%: 95% CI[0%, 4.8%]) and after EUS-guided FNA in two patients (4%: 95% CI[0%, 9.6%]). The difference was not statistically significant. None of these patients developed clinical signs of infection. Risk factors predisposing to bacteremia could not be identified. CONCLUSION: The frequency of bacteremia after EUS, with and without FNA, is within the range of that for diagnostic upper endoscopy. Therefore, the same recommendations for prophylactic administration of antibiotics to prevent endocarditis may be applied in patients undergoing EUS and EUS-guided FNA. The role of esophageal cancer as a predisposing factor to EUS-associated infection remains uncertain.